San Ramon

Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 on kidney function in adults with chronic kidney disease, some of whom may also have type 2 diabetes, and who are living with overweight or obesity. The study compares NNC0519-0130 with semaglutide, an existing medicine, and a placebo, which is a "dummy" treatment. This is a Phase 2 proof-of-concept and dose-finding study aimed at understanding how these treatments may reduce kidney damage. Participants will be randomly assigned to one of three groups receiving either NNC0519-0130, semaglutide, or placebo. All treatments are given by subcutaneous injection once weekly. The study treatment phase lasts up to 36 weeks, with assessments at weeks 12, 24, and 36 to monitor changes in kidney damage by measuring the urinary albumin-to-creatinine ratio. The overall study duration can be up to 43 weeks. During the study, participants will be regularly monitored through laboratory tests and clinical evaluations to assess kidney function and safety. Researchers will measure changes from the start of the study in the urinary albumin-to-creatinine ratio at multiple time points. Participants will also need to have stable doses of certain blood pressure medications before joining. Safety and treatment effects will be assessed throughout the study period.

Amblyopia, a common cause of reduced vision in one eye among children and young adults, affects between 1% and 5% of this population. It is often linked to conditions like uncorrected anisometropia and strabismus, which can also cause issues with focusing, eye coordination, depth perception, and contrast sensitivity. This research focuses on patients receiving Luminopia, an FDA-approved device treatment that uses therapeutic software to stimulate vision and manage amblyopia. This study observes patients who have been treated with Luminopia as part of their regular care without altering their treatment. Luminopia therapy involves using a device designed to improve vision in the weaker eye through specialized software. The registry collects clinical data from patients treated with Luminopia for at least 12 weeks, providing real-world insights into how the treatment is used by eye care professionals. Participants will be followed over several months with visits at 3, 6, 12, and 24 months to assess changes in visual acuity and stereoacuity, treatment duration, follow-up visits, and adherence to therapy. The study also measures how well improvements last after stopping treatment. Data is gathered through regular clinical assessments to help understand the effectiveness and durability of Luminopia treatment in everyday practice.

Researchers are evaluating whether the drug zilebesiran can reduce the risk of major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults who have hypertension that is not well controlled and who either have established cardiovascular disease or are at high risk for it. This Phase 3 global study is designed to continue until enough cardiovascular events have occurred to assess the treatment's effect. Participants will be randomly assigned to receive either zilebesiran or a placebo, both given as injections under the skin (subcutaneous administration). All participants will continue with their standard care, which includes treatment with at least two antihypertensive medications, one of which must be a diuretic such as a thiazide or loop diuretic. The study is double-blind, so neither participants nor researchers know who is receiving the active drug or placebo. During the study, participants will be closely monitored for cardiovascular events including heart attacks, strokes, heart failure hospitalizations, and cardiovascular deaths over approximately five years. Researchers will collect data on these events to determine the time until the first occurrence of any of these outcomes. Safety assessments and standard clinical evaluations will also be performed throughout the study period to ensure participant well-being.